Stevioside promotes hepatocyte proliferation via YAP signaling in cholestatic disease.

Wei Jiang Xu Fang Yi-Meng Sun Meng-Yuan Xu Xin Han Shuo-Jun Yan Xu Liu Ya-yun Liu Xian-Zhu Zeng Wen-Qiang Lai Jin-Quan Huang Bin Zhou Xiao-wei Meng Yong-Xu Zhao Yan Li

Aug 2026 · Acta Pharmacologica Sinica · 0 citations · 41 references

Medicine

TL;DR

It is established that stevioside repairs cholestatic injury by directly driving region-restricted hepatocyte proliferation via YAP signaling, highlighting its potential as a mechanistically innovative candidate for the treatment of cholestatic liver diseases.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Jan 2026

Loganin Ameliorates Cholestatic Liver Fibrosis by Inhibiting Hepatic Stellate Cell Autophagy and Activation Through EGFR Signaling

Liver cirrhosis represents the irreversible end‐stage of various chronic liver diseases, whereas hepatic fibrosis, characterized by hepatic stellate cell (HSC) activation, constitutes the critical pathological intermediate in this progression. In this study, we investigated the antifibrotic effects of loganin, a natura...

Xinwen Li, Hui-Ling Zhang, Chao Zhang et al. · Mediators of Inflammation · 0 citations

Open access Oct 2026

Luteolin protects against cholestasis by suppressing hepatocyte apoptosis through direct PI3K binding and AKT activation

It is confirmed that Lut directly targets PI3K to initiate the PI3K/AKT signaling cascade, and thereby suppresses bile acid-induced hepatocyte apoptosis, and refine the mechanistic understanding of Lut’s hepatoprotective action.

Xing-Liang Zhao, Ying Xu, Hong-Yan Liang et al. · Frontiers in Pharmacology · 0 citations

Open access Sep 2026

Restoring lysosomal proteostasis reverses steatohepatitis and fibrosis in experimental MASH.

The data indicate that this pharmacological restoration of lysosomal proteostasis engages key transcriptional regulators (Mediator complex) leading to the selective remodeling of pro-fibrotic and inflammatory pathways, leading to the selective remodeling of pro-fibrotic and inflammatory pathways.

Dylan Mastrippolito, Lauriane Gur, Malia Lasalo et al. · Pharmacological Research · 0 citations

Sep 2026

Chlorogenic Acid Attenuates Liver Fibrosis in Mice via HIF-1α Inhibition and M2 Macrophage Polarization.

INTRODUCTION Liver fibrosis, a key pathological step preceding cirrhosis, is characterized by the abnormal accumulation of extracellular matrix (ECM) components, a process largely driven by hepatic stellate cell activation and persistent chronic inflammation. Chlorogenic acid (CGA), a natural polyphenolic compound, has...

Yong-Qing Zhang, Lin Feng, T. Tang et al. · Current Medicinal Chemistry · 0 citations

Open access 2026

Saikosaponin D Ameliorates Non-alcoholic Steatohepatitis by Inhibiting STING-Mediated Macrophage M1 Polarization in Mice.

Saikosaponin D ameliorates NASH by inhibiting the STING-TBK1-IRF3/NF-κB axis in macrophages and promoting M1-to-M2 polarization, identifying SSd as a promising immunomodulatory therapy for NASH.

Wen-Jie Zhang, Yao-Hui Yin, Si-Qi Cheng et al. · Biological and Pharmaceutica... · 0 citations

Review Open access Sep 2026

Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Emerging therapeutics through a liver cell-centered framework are summarized, integrating hepatocyte-directed metabolic therapies, immune-cell modulation, hepatic stellate cell-targeted antifibrotic strategies, niche-directed approaches involving liver sinusoidal endothelial cells and cholangiocytes, systemic multi-cel...

Han-Yang Liu, Ming-Yuan Zhang, F. Tacke · Drug Design, Development and... · 0 citations